Dashboard
Manage Tickers

TCRXTScan Therapeutics, Inc.

Nasdaq tscan.com


$ 8.95 $ 0.08 (0.9 %)    

Friday, 17-May-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 8.98
$ 8.85
$ 0.00 x 0
$ 0.00 x 0
$ 8.76 - $ 9.00
$ 1.93 - $ 9.36
177,730
na
851.99M
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-09-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-19-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-initiates-coverage-on-tscan-therapeutics-with-buy-rating-announces-price-target-of-12
BTIG Initiates Coverage On TScan Therapeut...
05/16/2024 14:12:19

BTIG analyst Justin Zelin initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and announces Price Targe...

hc-wainwright--co-reiterates-buy-on-tscan-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on TSca...
05/14/2024 11:23:38

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

key-takeaways-from-tscan-therapeutics-analyst-ratings
Key Takeaways From TScan Therapeutics Anal...
05/13/2024 12:00:42

tscan-therapeutics-existing-cash-resources-of-1628m-along-with-the-1614m-net-proceeds-received-from-its-april-2024-underwritten-public-offering-will-provide-cash-runway-into-the-fourth-quarter-of-2026
TScan Therapeutics' Existing Cash Resource...
05/13/2024 11:07:57

tscan-therapeutics-q1-2024-gaap-eps-032-misses-026-estimate-sales-566000-miss-3975m-estimate
TScan Therapeutics Q1 2024 GAAP EPS $(0.32...
05/13/2024 11:05:35

needham-reiterates-buy-on-tscan-therapeutics-maintains-11-price-target
Needham Reiterates Buy on TScan Therapeuti...
05/13/2024 10:24:23

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11 price target.

tscan-therapeutics-doses-first-patient-in-phase-1-clinical-trial-evaluating-tcr-t-therapy-for-treatment-of-solid-tumors
TScan Therapeutics Doses First Patient In ...
05/09/2024 11:05:16

unveiling-4-analyst-insights-on-tscan-therapeutics
Unveiling 4 Analyst Insights On TScan Ther...
04/23/2024 18:01:19

wedbush-reiterates-outperform-on-tscan-therapeutics-maintains-10-price-target
Wedbush Reiterates Outperform on TScan The...
04/23/2024 17:17:01

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price tar...

tscan-therapeutics-prices-upsized-150m-public-offering-2472581-common-shares-at-713share
TScan Therapeutics Prices Upsized $150M Pu...
04/17/2024 06:13:22

TScan Therapeutics announces pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a pub...

tscan-therapeutics-reports-launch-of-125m-proposed-public-offering
TScan Therapeutics Reports Launch Of $125M...
04/16/2024 20:26:48

All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. The Company inte...

tscan-therapeutics-provides-update-on-its-solid-tumor-and-heme-malignancies-clinical-programs
TScan Therapeutics Provides Update On Its ...
04/16/2024 20:14:58

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for...

worthington-steel-posts-upbeat-results-joins-summit-midstream-partners-fedex-and-other-big-stocks-moving-higher-on-friday
Worthington Steel Posts Upbeat Results, Jo...
03/22/2024 14:08:47

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

barclays-maintains-overweight-on-tscan-therapeutics-raises-price-target-to-9
Barclays Maintains Overweight on TScan The...
03/07/2024 16:27:22

Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and raises the price target from ...

hc-wainwright--co-reiterates-buy-on-tscan-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on TSca...
03/07/2024 12:38:06

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

tscan-therapeutics-q4-earnings-insights
TScan Therapeutics: Q4 Earnings Insights
03/06/2024 13:45:06

tscan-therapeutics-q4-eps-021-beats-029-estimate-sales-721m-beat-334m-estimate-cash-balance-of-1920m-to-fund-its-current-operating-plan-into-2026
TScan Therapeutics Q4 EPS $(0.21) Beats $(...
03/06/2024 12:08:02

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(...

tscan-therapeutics-presents-updated-phase-1-clinical-results-on-tsc-100-and-tsc-101-at-the-2024-tandem-meetings-of-astct-and-cibmtr
TScan Therapeutics Presents Updated Phase ...
02/26/2024 12:16:00

tscan-therapeutics-will-host-a-virtual-key-opinion-leader-event-to-discuss-updated-results-from-its-phase-1-heme-malignancies-study-and-highlights-from-its-oral-presentation-at-the-2024-tandem-meetings-on-monday-february-26
TScan Therapeutics Will Host A Virtual Key...
02/14/2024 12:31:03

wedbush-reiterates-outperform-on-tscan-therapeutics-maintains-9-price-target
Wedbush Reiterates Outperform on TScan The...
02/01/2024 15:03:35

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $9 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION